Product Development and Innovation: Abbott launched several new products, including:
- TECNIS® Multifocal Low Add products in the U.S. for customized patient vision needs.
- WHITESTAR Signature® Pro system for cataract removal, integrated with iPad® apps for surgical efficiency.
- iDESIGN® Advanced WaveScan Studio System in the U.S. and China for personalized LASIK treatments.
- FreeStyle Libre Flash Glucose Monitoring System for diabetes care, eliminating routine finger pricks.
Future Developments: Abbott planned to continue developing next-generation equipment and consumables, including improvements to the LASIK platform and cataract surgery systems, and seek approvals for launching existing products in new markets.
Financial Review: The report details Abbott’s financial condition, cash flow, debt, and capital. Key points include:
- Net Sales: $20.4 billion, a 0.8% decrease compared to 2014. This was primarily due to unfavorable foreign exchange rates, which impacted sales by 6.4%.
- Operating Earnings: $2.9 billion, representing an increase from $2.3 billion in 2014.
- Net Earnings: $4.4 billion, significantly higher compared to $2.3 billion in 2014. This increase was largely attributed to after-tax specified items, including gains from the sale of developed market branded generics pharmaceuticals business.
- Earnings Per Share (EPS): $2.94 in 2015, up from $1.50 in 2014. Adjusted EPS, excluding specified items, was $2.15 in 2015 compared to $2.06 in 2014.
- Net Cash from Operating Activities: $3.0 billion in 2015.
- Long-term Debt Rating: A+ by Standard & Poor’s and A2 by Moody’s. The outlook was subject to adjustments due to the acquisition of Alere.
- Capital Expenditures: $1.1 billion, primarily for upgrading and expanding facilities and equipment.
- Dividends: $0.98 per share in 2015, reflecting a 9% increase from 2014.
Venezuela Operations: Revenue from Venezuela accounted for approximately 2% of Abbott’s total net sales, with pre-tax income of $200 million in 2015. However, the hyper-inflation and political uncertainty in Venezuela posed challenges.
Shareholder Information: The report includes details on stock listings, dividend dates, and shareholder services. Abbott’s common stock is listed on the New York Stock Exchange with the ticker symbol ABT.
Get access to the full report here:
Overall, Abbott Laboratories demonstrated strong performance in 2015, with significant achievements in product development, financial stability, and global market presence. The company’s diversified approach and focus on innovation were key drivers of its success, despite economic challenges in certain markets like Venezuela.
